VERTEX PHARMACEUTICALS INC / MA — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 32 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $3.19B | ↑+9.5% | $1.19B | — | 37.8% |
| 2025-09-30 | $3.08B | ↑+11.0% | $1.08B | ↑+3.6% | 38.6% |
| 2025-06-30 | $2.96B | ↑+12.1% | $1.03B | ↑+128.7% | 38.8% |
| 2025-03-31 | $2.77B | ↑+3.0% | $646M | ↓-41.2% | 22.7% |
| 2024-12-31 | $2.91B | ↑+15.7% | — | — | — |
| 2024-09-30 | $2.77B | ↑+11.6% | $1.05B | ↑+1.0% | 40.3% |
| 2024-06-30 | $2.65B | ↑+6.1% | $-3.59B | ↓-492.4% | -132.9% |
| 2024-03-31 | $2.69B | ↑+13.3% | $1.10B | ↑+57.1% | 42.4% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$3.19B
↑+9.5% +$278M YoY
Net Income
$1.19B
↑+41.9% +$352M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
VRTX Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyVRTX Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics